Intensive Insulin Therapy in Patients with Type 1 Diabetes Mellitus

Endocrinology and Metabolism Clinics of North America

Volumn 41, Issue 1, 2012, Pages 89-104

  Switzer, Sean M ^a   Moser, Emily G ^a,b   Rockler, Briana E ^a   Garg, Satish K ^a,b,c  

^a UNIVERSITY OF COLORADO DENVER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c Diabetes Technology and Therapeutics   (United States)

Author keywords

Diabetes mellitus; Glucose control; Glucose Monitoring; Insulin analogs; Insulin therapy

Indexed keywords

ANTIDIABETIC AGENT; CITRIC ACID; EDETIC ACID; GLUCOSE; HEMOGLOBIN A1C; HYALURONIDASE; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DEGLUDEC; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LONG ACTING INSULIN; LY 2605541; RECOMBINANT HUMAN INSULIN; SHORT ACTING INSULIN; UNCLASSIFIED DRUG;

ARTIFICIAL PANCREAS; BLOOD GLUCOSE MONITORING; BOLUS INJECTION; CONTINUOUS GLUCOSE MONITOR; CONTINUOUS INFUSION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE REDUCTION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN TREATMENT; INTENSIVE CARE; MACROVASCULAR DISEASE; MEDICAL TECHNOLOGY; MICROANGIOPATHY; MONITOR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ONSET AGE; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SELF MONITORING; UNITED STATES; VASCULAR DISEASE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN;

EID: 84860611956     PISSN: 08898529     EISSN: 15584410     Source Type: Journal    
DOI: 10.1016/j.ecl.2011.12.001     Document Type: Review

References (65)

1. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States 2011. Available at:. Accessed August 26, 2011. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf.
2. Huang E.S., Basu A., O'Grady M., et al. Projecting the future diabetes population size and related costs for the US. Diabetes Care 2009, 32:2225-2229.
3. Diabetes and prediabetes cost in the U.S. $218 billion in 2007: en route to $336 billion by 2034 2010, Diabetes Health, Available at:, Accessed August 26, 2011. http://diabeteshealth.com/read/2010/02/03/6551/diabetes-and-pre-diabetes-cost-the-us-218-billion-in-2007-en-route-to-336-billion-by-2034/.
4. Diabetes and pre-diabetes accounted for $218 billion in costs in 2007, health affairs paper demonstrates 2008. Available at:. Accessed August 26, 2011. http://press.novonordisk-us.com/index.php%3Fs=43%26item=230.
5. Yang W., Lu J., Weng J., et al. China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 2010, 362:1090-1101.
6. Anjana R.M., Pradeepa R., Deepa M., et al. Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: Phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR - INDIAB) study. Diabetologia 2011, 10.1007/s00125-011-2291-5.
7. International Diabetes Federation IDF Diabetes Atlas 2011, International diabetes federation, Brussels (Belgium), Available at:, Accessed November 11, 2011. http://eatlas.idf.org, 5th edition.
8. Garg S.K. Rising epidemic of diabetes and hypertension in Asia. Diabetes Technol Ther 2011, 14(1). 10.1089/dia.2011.0257.
9. Atkinson M.A., Eisenbarth G.S. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001, 358:221-229.
10. Onkamo P., Vonnen S., Karvonen M., et al. Worldwide increase in incidence of Type 1 diabetes-the analysis of the data on published incidence trends. Diabetologia 1999, 42:1395-1403.
11. Imagawa A., Toshiaki H., Jun-ichiro M., et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and absence of diabetes-related antibodies. N Engl J Med 2000, 342:301-307.
12. Verge C.F., Stenger D., Bonifacio E., et al. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: combinatorial islet autoantibody workshop. Diabetes 1998, 47(12):1857-1866.
13. Greenbaum C.J. Insulin resistance in type 1 diabetes. Diabetes Metab Res Rev 2002, 18(3):192-200.
14. Abdul-Rasoul M., Habib H., Al-Khouly M. 'The honeymoon phase' in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes 2006, 7(2):101-107.
15. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
16. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003, 290:2159-2167.
17. Ratner R.E., Diabetes Prevention Program Research An update on the diabetes prevention program. Endorc Pract 2006, 12(1):20-24.
18. Hirsch I.B. Insulin delivery devices-pumps and pens. Diabetes Technol Ther 2010, 12(Suppl 1):S115-S116.
19. Pickup J.C., Renard E. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 2008, 31(Suppl 2):S140-S145.
20. Garg S.K., Ellis S.L., Ulrich H. Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 2005, 6(4):1-9.
21. Rosenstock J., Dailey G., Massi-Benedetti M., et al. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005, 28(4):950-955.
22. Owens D.R., Bolli G.B. Beyond the era of NPH insulin-long-acting insulin analogs: chemistry comparative pharmacology, and clinical application. Diabetes Technol Ther 2008, 10:333-349.
23. Zinman B., Fulcher G., Rao P.V., et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomized, open-label, phase 2 trial. Lancet 2011, 377:924-931.
24. Kudra Y., Basu A. Ultra-long-acting insulins for lifestyle-related pandemic. Lancet 2011, 377:880-889.
25. Birkeland K., Home P., Wendish U., et al. Insulin degludec in type 1 diabetes: a randomized controlled trial of new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011, 34(3):661-665.
26. Radermecker R.P., Scheen A.J. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin: efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004, 20(3):178-188.
27. Vaughn D.E., Yocum R.C., Muchmore D.B., et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther 2009, 11:345-352.
28. del Olmo M.I., Campos V., Abellan P., et al. A case of lipoatrophy with insulin detemir. Diabetes Res Clin Pract 2008, 80(1):e20-e21.
29. Garber A.J. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006, 66(1):31-49.
30. Steiner S., Hompesch M., Pohl R., et al. A novel insulin formulation with a more rapid onset of action. Diabetologia 2008, 51:1602-1606.
31. Meneghini L., Sparrow-Bodenmiller J. Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections. Diabetes Technol Ther 2010, 12(Suppl 1):109-114.
32. Skyler J.S. Continous subcutaneous insulin infusion-a historical perspective. Diabetes Technol Ther 2010, 12(Suppl 1):S5-S9.
33. Anhalt H., Bohannon N.J. Insulin patch pumps: their development and future in closed-loop systems. Diabetes Technol Ther 2010, 12(Suppl 1):S51-S58.
34. Scaramuzza A.E., Zuccotti G.V. Commentary on 'Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus' with a response from the review authors. Evid Base Child Health 2010, 5:1870-1872.
35. Maahs D.M., Horton L.A., Chase H.P. The use of insulin pumps in youth with type 1 diabetes. Diabetes Technol Ther 2010, 12(Suppl 1):S51-S58.
36. Pickup J.C., Kidd J., Burmiston S., et al. Determinants of glycaemic control in type 1 diabetes during intensified therapy with multiple daily insulin injections or continuous subcutaneous insulin infusion: importance of blood glucose variability. Diabetes Metab Res Rev 2006, 22:232-237.
37. Pickup J.C., Mattock M.B., Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared to intensive insulin injection therapy in type 1 diabetes: meta-analysis of randomized controlled trials. BMJ 2002, 324:705-708.
38. Pickup J.C., Kidd J., Burmistion S., et al. Effectiveness of continuous subcutaneous insulin infusion in hypoglycaemic-prone type 1 diabetes: implications for NICE guidelines. Pract Diabet Int 2005, 22:10-14.
39. Retnakaran R., Hochman J., DeVries J.H., et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baselin A1c. Diabetes Care 2004, 27:2590-2596.
40. Burdick J., Chase H.P., Slover R.H., et al. Missed insulin meal boluses and elevated hemoglobin A1c levels in children receiving insulin pump therapy. Pediatrics 2004, 113:221-224.
41. Linkeschova R., Raoul M., Bott U., et al. Less severe hypoglycaemia, better metabolic control, and improved quality of life in type 1 diabetes mellitus with continuous subcutaneous insulin infusion (CSII) therapy; an observational study of 100 consectutive patients followed for a mean of 2 years. Diabet Med 2002, 19:746-751.
42. Garg S.K., Hirsch I.B. Self-monitoring of blood glucose. Int J Clin Pract 2010, 64(Suppl):1-10. 10.1111/j.1742-1241.2009.02271.x.
43. Freckmann G., Baumstark A., Jendrike N., et al. System accuracy evaluation of 27 blood glucose monitorying systems according to DIN EN ISO 15197. Diabetes Technol Ther 2010, 12:245-247.
44. Hirsch I.B., Verderese C.A. Interference of home blood glucose measurements and poor outcomes: a solvable problem requiring broader exposure. Diabetes Technol Ther 2010, 12:245-247.
45. Garg S.K. Role of continuous glucose monitoring in patients with diabetes using multiple daily insulin injections. Infusystems International 2009, 8:17-21.
46. Garg S.K., Hoff H.K., Chase H.P. The role of continuous sensors in diabetes care. Endocrinol Metab Clin North Am 2004, 33:163-173.
47. Gilliam L.K., Hirsch I.B. Practical aspects of real-time continuous glucose monitoring. Diabetes Technol Ther 2009, 11:93-103.
48. Ellis S.L., Bookout T., Garg S.K., et al. Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am 2007, 36(Suppl 2):46-48.
49. Garg S.K., Zisser H., Schwartz S., et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care 2006, 29:44-50.
50. Garg S.K., Potts R.O., Ackerman N.R., et al. Correlation of fingerstick blood glucose measurements with Gluco Watch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care 1999, 22:1708-1714.
51. Kovatchev B.P., Brenton M., Man C.D., et al. In Silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009, 3(1):44-55.
52. Steil G.M., Panteleon A.E., Rebrin K. Closed-loop insulin-delivery-the path to physiological glucose control. Adv Drug Deliv Rev 2004, 56:125-144.
53. Hovorka R. Continuous glucose monitoring and closed-loop systems. Diabet Med 2005, 23:1-12.
54. Mazze R., Strock E., Borgman S. Evaluating the accuracy, reliability, and clinical applicability of continuous glucose monitoring (CGM): Is CGM ready for real time?. Diabetes Technol Ther 2009, 11:11-18.
55. Selam J.L. External and implantable insulin pumps: current place in the treatment of diabetes. Exp Clin Endocrinol Diabetes 2001, 109:S333-S340.
56. Weinzimer S.A., Steil G.M., Swan K.L., et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2010, 33:121-127.
57. Danne T., Kordonouri O., Holder M., et al. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011, 10:1129-1134.
58. El-Khatib F.H., Russel S.J., Nathan D.M., et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010, 2:27ra.
59. Castle J.R., Engle J.M., El Youssef J., et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010, 33:1282-1287.
60. Henquin J.C. Perspectives in diabetes: triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 2000, 49:1751-1760.
61. Kilpatrick E.S., Rigby A.S., Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006, 29(7):1486-1490.
62. White N.H., Chase H.P., Arslanian S., et al. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 2009, 32(3):387-393.
63. Monnier L., Mas E., Ginet C., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006, 295(14):1681-1687.
64. Mohsin F., Craig M.E., Cusumano J., et al. Discordant trends in microvascular complications in adolescents with type 1 diabetes from 1990 to 2002. Diabetes Care 2005, 28:1974-1980.
65. Hirsch I.B., Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control?. J Diabetes Complications 2005, 19:178-181.